Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4004 participants
OBSERVATIONAL
2022-06-01
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography
NCT03632785
Kitasato PCI Registry
NCT05308329
Correlation Between Coronary and Carotid Atherosclerotic Disease and Links With Clinical Outcomes
NCT02114541
Intracoronary Features in the Prognosis of Endothelial Dysfunction and MACES in Population With Acute Coronary Syndrome
NCT03583047
Non Invasive Multicenter Italian Study for Coronary Artery Disease
NCT00539604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For decades, patients with obstructive coronary disease, specifically with lesions above 70%, have been the subject of numerous randomized studies and meta-analyses concerning the influence of drug treatments, revascularization (surgical or percutaneous), and lifestyle on their prognosis. In this scenario, the investigators already have a reasonable knowledge of the behaviors most appropriate for both avoiding events and alleviating symptoms. However, one particular subgroup consists of patients whose lesions are non-obstructive. In most cases, these are considered lesions of ≤70%. Many individuals presented obstructive lesions that were deemed appropriate for angioplasty within this classification. For example, in the study Defer of 325 patients with indications of ischemia, 44.3% presented FFR (fractional flow reserve) ≤0.75, which suggested significant obstruction, and were submitted to ATC. Thus, the investigators consider the threshold ≤70% inappropriate since it includes many patients with ischemia when assessed by FFR. Therefore, this study has decided to investigate patients with lesions of ≤50% on the supposition that they do not have obstructive lesions. In addition, although coronary disease may follow a stable clinical course, this is not the case with atherosclerotic plaques. These can grow, become complex, stabilize and reinitiate new cycles of growth/destabilization/stabilization or inactivity, in either the presence or absence of evident symptoms. Though aware of this dynamic, studies were performed to "photograph" at a given time subclinical atherosclerotic load and correlate it to the incidence of the events. The indicators most used for evaluating atherosclerotic load have been the presence of extra-cardiac atherosclerosis (carotid ultrasound) and calcification of the coronary arteries. Furthermore, the calcium score has been used for the same purpose in the Brazilian population: but only as a prognostic indicator among carriers of family hypercholesterolemia. However, there are considerable doubts concerning therapeutic interventions in asymptomatic patients with no critical stenosis. Given this gap, chiefly among the Brazilian population, and being an institution with one of the highest volumes of medical care and screening for coronary disease globally, the investigators have all the necessary conditions to put this important public health problem into perspective.
Objectives:
To evaluate clinical evolution, in eight years, of patients with no coronary lesions or lesions \<50%, invasive coronary angiography (ICA) exams or coronary angiotomography is performed for the diagnosis of coronary disease.
Population:
Patients were referred to Instituto do Coração (InCor HCFMUSP) for ICA or angiotomography for diagnosis of coronary heart disease from January 1, 2011, to December 31, 2017. Exclusion criteria: age under 18 years or over 80 years at the time of examination, previous history of an acute coronary syndrome (infarction and unstable angina), revascularization interventions (surgical or percutaneous), valvular heart disease, cardiomyopathies, or diseases with a poor prognosis (expected survival of fewer than eight years). The cohort will be composed of 3 groups: the control group (without coronary lesions), lesion group \<30%, and lesion group \>30% to \<50%. Study type: an observational, retrospective, with data from the database of InCor, (Heart Institute - InCor, University of São Paulo). Outcomes: primary composite (general death, acute myocardial infarction, cerebrovascular accident, need for revascularization); secondary outcomes: the isolated components of the primary outcome at eight years.
Data to be collected:
Age (on the date of examination), gender, presence of risk factors - arterial hypertension (BP \>130/85; or use of antihypertensive medication), diabetes mellitus (fasting glucose ≥126 mg/dL, casual \>140 mg/dL or GTT \>200 mg/dL, or use of oral or injectable hypoglycemic agents), dyslipidemia (LDL \>130 mg/dL, triglycerides \>150 mg), lipid levels (total cholesterol, HDL-C, LDL-C, and triglycerides); tobacco user (never, ex-tobacco user, active), obesity, exercise, family history, creatinine, chronic kidney disease (glomerular filtration \<60 mL/1.73m²/min).
Medications in use: ACE inhibitors/ARB; statins; AAS; Beta-blockers and calcium channel antagonists, and diuretics.
Clinical status: angina and/or dyspnea. Left ventricular systolic function: normal left ventricular ejection fraction (LVEF) (50%), mild decrease (≥45% to \<50%); moderate (\>35% to 45%) and severe (\<35%).
Cardiovascular history: cerebrovascular accident or peripheral arterial disease.
Atherosclerotic load: a) Higher percentage of obstruction of the lumen by comparing the diameter in the lesion region with its proximal neighborhood: absent (0%), very mild (1-30%), and mild (30-49%), for eligibility of each group studied; b) Total lesion score: zero for absence, 1 for minor injuries(\<30%), and 2 for minor injuries(30-50%). Multiplied by their frequency and totaled at the end; c) The atherosclerotic load will be weighted using the Syntax scores for its location, though the lesions are less than 50%. Left coronary trunk = 5; proximal AD = 3.5; medial AD = 1.5; distal AD = 1; diagonal = 1; proximal circumflex = 1.5; distal = 1; marginal = 1; proximal or distal right coronary artery = 1 and posterior descending artery = 1; coronary calcium score (CAC).
Population:
Patients underwent invasive coronary angiography (ICA) or coronary computed tomography angiography at InCor from January 2011 to December 2014. To allow 5-year follow-up (FU) of all cases. The investigators estimate the inclusion of approximately 5,000 patients, with a minimum of 1,500 in the control group.
Deadlines for execution and analysis:
The investigators anticipate including an average of 40 patients per day and completion at the end of 2 years. The rate of scheduled events should not exceed 0.5% to 1% per year, so the investigators plan interim analyses at two years FU when the investigators would have at least 600 events for analysis.
Clinical, laboratory, and image data:
Electronic Patient Care System SI3 of InCor will be used to screen and follow the patients. Patients who have not been followed regularly at ambulatory clinics of InCor will be contacted by phone or e-mail to ascertain their evolution. In cases of death, family members or attending physicians will be contacted. Death certificates will be analyzed to adjudicate death´s causes. Eventually, the Foundation for the State System of Data Analysis (SEADE) database from Estado de São Paulo will be used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group (without coronary lesions)
Cohort control group. No interventions.
No intervention
No intervention. It is an observational study
Coronary Lesion < 30%
Participants with coronary lesion under 30%. No interventions.
No intervention
No intervention. It is an observational study
Coronary Lesion > 30% and < 50%
Participants with coronary lesions greater than 30% and under 50%. No interventions.
No intervention
No intervention. It is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention. It is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous history of acute coronary syndrome (infarction and unstable angina);
* Revascularization interventions (surgical or percutaneous);
* Valvular heart disease;
* Cardiomyopathies;
* Diseases with a poor prognosis (expected survival of less than 8 years).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Protasio Luz, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Makarovic Z, Makarovic S, Bilic-Curcic I, Mihaljevic I, Mlinarevic D. NONOBSTRUCTIVE CORONARY ARTERY DISEASE - CLINICAL RELEVANCE, DIAGNOSIS, MANAGEMENT AND PROPOSAL OF NEW PATHOPHYSIOLOGICAL CLASSIFICATION. Acta Clin Croat. 2018 Sep;57(3):528-541. doi: 10.20471/acc.2018.57.03.17.
Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, Patel MR, Sandhu A, Valle J, Magid DJ, Leon B, Bhatt DL, Fihn SD, Rumsfeld JS. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014 Nov 5;312(17):1754-63. doi: 10.1001/jama.2014.14681.
Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001 Jun 19;103(24):2928-34. doi: 10.1161/01.cir.103.24.2928.
Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Sep 24;74(12):1608-1617. doi: 10.1016/j.jacc.2019.08.012.
McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, Bild DE, Shea S, Liu K, Watson KE, Folsom AR, Khera A, Ayers C, Mahabadi AA, Lehmann N, Jockel KH, Moebus S, Carr JJ, Erbel R, Burke GL. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015 Oct 13;66(15):1643-53. doi: 10.1016/j.jacc.2015.08.035.
Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibanez B, Lopez-Melgar B, Laclaustra M, Oliva B, Mocoroa A, Mendiguren J, Martinez de Vega V, Garcia L, Molina J, Sanchez-Gonzalez J, Guzman G, Alonso-Farto JC, Guallar E, Civeira F, Sillesen H, Pocock S, Ordovas JM, Sanz G, Jimenez-Borreguero LJ, Fuster V. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015 Jun 16;131(24):2104-13. doi: 10.1161/CIRCULATIONAHA.114.014310. Epub 2015 Apr 16.
Ostgren CJ, Soderberg S, Festin K, Angeras O, Bergstrom G, Blomberg A, Brandberg J, Cederlund K, Eliasson M, Engstrom G, Erlinge D, Fagman E, Hagstrom E, Lind L, Mannila M, Nilsson U, Oldgren J, Ostenfeld E, Persson A, Persson J, Persson M, Rosengren A, Sundstrom J, Swahn E, Engvall JE, Jernberg T. Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study. Eur J Prev Cardiol. 2021 Apr 23;28(3):250-259. doi: 10.1177/2047487320909300. Epub 2020 Mar 3.
Gorgulho B, Alves MA, Teixeira JA, Santos RO, de Matos SA, Bittencourt MS, Bensenor I, Lotufo P, Marchioni DM. Dietary patterns associated with subclinical atherosclerosis: a cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) study. Public Health Nutr. 2021 Oct;24(15):5006-5014. doi: 10.1017/S1368980020005340. Epub 2021 Jan 8.
Miname MH, Bittencourt MS, Moraes SR, Alves RIM, Silva PRS, Jannes CE, Pereira AC, Krieger JE, Nasir K, Santos RD. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. JACC Cardiovasc Imaging. 2019 Sep;12(9):1797-1804. doi: 10.1016/j.jcmg.2018.09.019. Epub 2018 Nov 15.
Pagidipati NJ, Peterson ED. Should Cardiovascular Preventive Therapy Be Over-the-Counter? J Am Coll Cardiol. 2021 Sep 14;78(11):1124-1126. doi: 10.1016/j.jacc.2021.07.020. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BARD Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.